Rhythm Pharmaceuticals, Inc. (RYTM): Total Liabilities
$210.17M
As of 2025-12-31
$219.97M
As of 2026-06-30
+21.1%
3-year compound annual growth
+59.2%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $210.17M | -7.7% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $227.72M | +39.7% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $162.99M | +37.9% | 2025-02-28, Balance as of period end |
| 2022-12-31 | $118.22M | +160.6% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $45.37M | +120.8% | 2023-03-01, Balance as of period end |
| 2020-12-31 | $20.55M | -25.3% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $27.50M | +97.1% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $13.95M | +100.8% | 2020-03-02, Balance as of period end |
| 2017-12-31 | $6.95M | +37.8% | 2019-03-08, Balance as of period end |
| 2016-12-31 | $5.04M | n/a | 2018-03-12, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $210.17M | -7.7% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $397.87M | -7.7% |
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $65.98M | +55.1% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $28.52M | -23.6% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $262.35M | -13.0% |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | $697.32M | +10.4% |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $465.08M | +6.5% |
| Amarin Corp PLC (AMRN) | 2025-12-31 | $211.49M | +6.2% |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $161.76M | +37.5% |
Compare RYTM, MRVI, STOK, LFVN side by side · Screen every company in Pharmaceutical Preparations ↗